tirzepatide and hormones Shown to Tackle Hypogonadism” from ENDO 2025: 📰 CME INDIA – Clinical Pearls: Tirzepatide in Obesity-Associated Hypogonadism @Rssdi_official @IndiaESI @AskDrShashank @banshisaboo @DrAmbrishMithal @dramitaol @KapoorNitinDr @DrShubhaSandill protocol:bariatric-pureed Flavor:Lemon Lime Retatrutide TFA (LY3437943 TFA)

tirzepatide and hormones Shown to Tackle Hypogonadism” from ENDO 2025: 📰 CME INDIA – Clinical Pearls: Tirzepatide in Obesity-Associated Hypogonadism @Rssdi_official @IndiaESI @AskDrShashank @banshisaboo @DrAmbrishMithal @dramitaol @KapoorNitinDr @DrShubhaSandill protocol:bariatric-pureed Flavor:Lemon Lime Retatrutide TFA (LY3437943 TFA)

Retatrutide TFA (LY3437943 TFA) | GCGR/GIPR/GLP-1R Agonist | MedChemExpress

The clinical data for orforglipron is promising, and Eli Lilly plans to submit it for FDA approval as a weight loss treatment in 2025 (and for type 2 diabetes in 2026)

protocol:bariatric-pureed

Flavor:Lemon Lime

Increase your dose every 4 weeks as tolerated, until a maximum dose of 15 mg is reached